On Aug. 23, 2021, Dynavax Technologies and Biological E announced the execution of a commercial supply agreement of Dynavax’s CpG 1018TM advanced adjuvant, for use in BE’s subunit COVID-19 vaccine candidate, CORBEVAXﾙ. The commercial supply agreement extends through 2022.

The agreement included doses for delivery in 2021, which were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax.